Study Overview
Anaerobutyricum soehngenii, a safe and beneficial gut microbe, has shown promise in improving insulin sensitivity in people at risk for type 2 diabetes. A recent study tested its long-term effects over three months with 98 prediabetic adults in Europe and the U.S.
Key Findings
- Improved Glycemic Control: Participants taking A. soehngenii had a 6% better overall glycemic control and a 1 mmol/mol reduction in HbA1c levels.
- Reduced Blood Pressure: Diastolic blood pressure decreased by 3 mm Hg in those treated with A. soehngenii.
- Well-Tolerated: The treatment was safe with no negative effects on gut microbiota, except for an increase in A. soehngenii levels.
- Better Response in U.S. Participants: U.S. subjects showed a 15% improvement in glucose tolerance tests.
Practical Healthcare Solutions
Measurable Outcomes
Clinics can set clear goals to monitor improvements in glycemic control and blood pressure in patients at risk for type 2 diabetes.
AI Tools for Clinical Needs
Select AI solutions that can help track and analyze patient data related to A. soehngenii supplementation.
Implementation Steps
Start with a pilot project to test the effects of A. soehngenii in a clinical setting, using AI tools to measure real-world outcomes.
Contact Us for More Information
For AI solutions in medical management, reach out via:
